ASCO 2023 | Phase II trial of patritumab deruxtecan in metastatic breast cancer

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, discusses findings from a Phase II trial (NCT04699630) of patritumab deruxtecan (HER3-DXd), an antibody drug conjugate (ADC), in patients with metastatic breast cancer. Clinical activity was recorded in patients with varying levels of HER3 expression, and the investigational drug was well tolerated. An additional expansion cohort will additionally assess HER3-DXd in patients pretreated with other ADCs such as trastuzumab emtansine or sacituzumab govitecan. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.